The sickle gene is widespread among many tribal population groups in India with prevalence of heterozygotes varying from 1-40 per cent. Co-inheritance of the sickle gene with β-thalassaemia, HbD Punjab and glucose-6-phosphate dehydrogenase (G6PD) deficiency has also been reported. Most of the screening programmes in India now use high performance liquid chromatography (HPLC) analysis although the solubility test is also sensitive and cheap. Sickle cell disease (SCD) among tribal populations is generally milder than among non-tribal groups with fewer episodes of painful crises, infections, acute chest syndrome and need for hospitalization. This has partly been attributed to the very high prevalence of α-thalassaemia among these tribes as well as higher foetal haemoglobin levels. However, the clinical presentation is variable with many cases having a severe presentation. There is not much information available on maternal and perinatal outcome in tribal women with sickle cell disease. Newborn screening programmes for SCD have recently been initiated in Maharashtra, Gujarat, Odisha and Chattisgarh and monitoring these birth cohorts will help to understand the natural history of SCD in India. Prenatal diagnosis is acceptable by tribal families in India. The Indian Council of Medical Research and the National Rural Health Mission in different states are undertaking outreach programmes for better management and control of the disease.
Introduction
Sickle cell disease(SCD) is one of the most common monogenic disorders globally with an autosomal recessive inheritance 1 . James Herrick, a physician first described the characteristic sickle shaped red cells in a medical student from Grenada in 1910. Linus Pauling and his colleagues showed that sickle haemoglobin (HbS) had an altered electrophoretic mobility and they were the first to define it as a molecular disease in 1949. A few years later in 1957, Vernon Ingram discovered that sickle haemoglobin resulted from a single amino acid substitution in the haemoglobin molecule 2,3, . The disease results from a single base A>T mutation in the triplet encoding the sixth residue of the β-globin chain, leading to a substitution of valine for glutamic acid and the abnormal haemoglobin S (HbS).
The primary pathophysiology is based on the polymerization of deoxyHbS with formation of long fibers within the RBCs causing a distorted sickle shape which eventually leads to increased haemolysis and vaso-occlusion of sickle red cells. However, the clinical presentation of SCD patients is extremely variable and there are several events that may trigger vasoocclusion. Recent work has shown the importance of red cell dehydration, abnormal adhesion of RBCs to the vascular endothelium, imflammatory events, and activation of all the cells in the vessel and abnormalities of nitric oxide metabolism in the pathophysiology of this multi-organ disease 4 .
The sickle gene is an example of balanced polymorphism. Heterozygotes have a selective advantage and are protected against Plasmodium falciparum malaria while there is an increased premature death rate of homozygotes 2 .
The tribal populations of India
India has the largest concentration of tribal populations globally. They are believed to be the early settlers in the country and are considered to be the original inhabitants. According to the Census of India 2011 5 , the tribal population of India is 8.6 per cent of the total population which is about 67.8 million people. The States of Madhya Pradesh, Maharashtra, Odisha, Gujarat, Rajasthan, Jharkhand, Chhattisgarh, Andhra Pradesh, West Bengal and Karnataka account for around 83 per cent of the total scheduled tribe population in the country and majority of these tribal groups live in rural areas. In all, 461 scheduled tribes have been listed 6 and they have their own characteristic cultural patterns, languages and social systems, by and large keeping to themselves. However, Reich et al 7 concluded that "several thousand years ago, the entire subcontinent underwent a period of massive intermarriage, shuffling its population's genetic deck so thoroughly that it left clear traces even in the genomes of today's most isolated tribes".
Prevalence of sickle gene in tribal communities in India
The first description of sickle haemoglobin in India was by Lehman and Cutbush in 1952 In Maharashtra, the sickle gene is widespread in all the eastern districts, also known as the Vidarbha region, in the Satpura ranges in the north and in some parts of Marathawada. The prevalence of sickle cell carriers in different tribes varies from 0 to 35 per cent. The tribal groups with a high prevalence of HbS (20-35 %) include the Bhils, Madias, Pawaras, Pardhans and Otkars. It has also been estimated that Gadchiroli, Chandrapur, Nagpur, Bhandara, yoetmal and Nandurbar districts would have more than 5000 cases of sickle cell anaemia 13 .
The entire tribal population of 1,25,000 individuals in the Wayanad district of Kerala was screened, followed by genetic counselling where carriers of HbS were advised not to marry carriers 19 . A very high prevalence of HbS is seen in these tribes (18.2 to 34.1 %) 20 .
In Gujarat, the Dhodia, Dubla, Gamit, and Naika tribes have a high prevalence of HbS (13-31 %) 10 . More recently very extensive population surveys have been done by the Indian Red Cross Society, Gujarat State Branch where 1,68,498 tribals from 22 districts were screened and the overall prevalence of sickle cell carriers was 11.37 per cent 21 . Some tribal groups in south Gujarat like Chaudry, Gamit, Rohit, Vasava and Kukana have shown both a high prevalence of HbS (6.3 to 22.7%) as well as β-thalassaemia trait (6.3 to 13.6 %) 22 . These tribal groups would have the likelihood of co-inheriting both these genes.
In a large multicentre study 23 where 15200 individuals from 14 primitive tribes from Maharashtra, Gujarat, Tamil Nadu and Odisha were screened, the HbS allele frequency varied from 0.011 to 0.120 and β-thalassaemia allele frequency varied from 0.005 to 0.024. Associated iron deficiency was seen in 26.2 per cent of sickle heterozygotes as well as in 67. 7 Apart from HbS, β-thalassaemia is also prevalent in some tribal populations with the frequencies being as high as 6 to 14 per cent in some tribes from Gujarat and Odisha 22, 26 . However, only a few HbS-β-thalassaemia cases have been reported among tribal populations. Seven cases (age 7 to 21 yr) were reported by Mukherjee et al in 2010 27 and they were either asymptomatic or were mild with only occasional episodes of vaso-occlusive crises. All of them had the β 0 mutation, codon 15(G>A) and the presence of associated α-thalassaemia. Earlier studies from Odisha showed the presence of HbS-β + -thalassaemia with the IVS 1-5 (G→C) mutation. These cases had low HbA levels(3-5%)
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. With migration for work and some intermixing over the years, co-inheritance of HbS with HbD Punjab, HbE and HbC has also been occasionally reported [29] [30] [31] .
Appropriate technologies for screening
Most of the early studies on epidemiology of sickle haemoglobin in different parts of the country used the sickling or the solubility test and in many reports this was followed by Hb electrophoresis to determine the phenotypes. However, in recent years, high performance liquid chromatography (HPLC) analysis has been used in many large programmes to identify carriers of both sickle haemoglobin as well as β-thalassaemia. Capillary electrophoresis has also now been introduced at some centres. Nonetheless, even the simple and cost-effective solubility test has been shown to have a sensitivity and specificity of 97.4 and 100 per cent, respectively in comparison to HPLC and could still serve as a good first line screen for sickle haemoglobin in remote areas where other facilities are not available 32 .
Newborn screening for sickle cell disorders
Newborn screening for sickle cell disorders was first offered in the New York Programme in 1975 33 , shortly after Robert Guthrie introduced dried blood specimen collection on filter paper 34 . Susequently, in USA all the States initiated newborn screening and this has also been undertaken in many other countries where the sickle gene is common. Either universal or targeted screening approaches have been used and the technology of choice has been isoelectric focusing (IEF) or HPLC 35 . Some programmes have now also introduced screening of β-thalassaemias and other haemoglobinopathies. Follow up and care of birth cohorts over several years have helped to understand the natural history of sickle cell disease and reduce early morbidity and mortality in these countries.
In India, newborn screening programmes for sickle cell disorders among tribal and non-tribal populations have only recently been initiated during the last three to five years in south Gujarat, Maharashtra, Chhattisgarh, Odisha and Madhya Pradesh [36] [37] [38] [39] . In the Kalahandi district in Odisha, 1668 newborns were screened and 19.03 per cent of tribals were sickle heterozygous and 36 babies with sickle cell anaemia were identified 37 . In Raipur in Chhattisgarh, a pilot study was undertaken where 1158 neonates were screened and 5.2 per cent were sickle heterozygous, five babies had sickle cell anaemia and one had sickle-β-thalassaemia 38 . In Nagpur in Maharashtra, a targeted screening approach was used where 1162 babies of sickle heterozygous mothers were screened and 536 babies were sickle cell carriers, 88 babies were sickle homozygous, four had sickle -β-thalassaemia and two had HbSD disease
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. In Valsad district in south Gujarat, 5467 babies from tribal communities were screened and 12.5 per cent were sickle cell carriers, 33 babies had sickle cell anaemia and 13 had sickle-β-thalassaemia
. In Jabalpur in Madhya Pradesh, newborn screening has just been initiated. In all these studies, heel prick/cord blood samples were collected on Guthrie cards or in EDTA vials and analysed by HPLC. Some of these birth cohorts are being followed up with comprehensive care in the respective sickle cell clinics and will eventually help to understand the natural history of sickle cell disease in India.
Co-inheritance of the sickle gene with G6PD deficiency
Usually G6PD deficiency has no significant effect in patients with sickle cell anaemia. However, a recent study has shown that concomitant G6PD deficiency worsens anaemia and increases blood transfusion requirements in infancy and early childhood upto two years of age but subsequently has little effect 40 . G6PD deficiency is prevalent in many tribal groups in India 10 . A cross-section of 15 major tribal communities from different parts of Odisha was randomly screened for haemoglobin variants and G6PD deficiency and high frequencies of sickle cell haemoglobinopathy (0-22.4%) and G6PD deficiency (4.3 to 17.4%) were found with 12 individuals inheriting both these abnormalities 41 . Among the 14 primitive tribal populations from four different States showing a high frequency of sickle gene, the prevalence of G6PD deficiency varied from 0.7 to 15.6 per cent 42. Thus, it may be important to screen for G6PD deficiency in newborn screening programmes for sickle cell disorders.
Clinical presentation and care of sickle cell disease cases in tribal regions
By and large, sickle cell disease in India where the β S gene is linked to the Arab-Indian haplotype which is associated with a mutation in the G γ-gene leading to increased HbF levels is not as severe as that in African populations. Tribal populations also have a high prevalence of α-thalassaemia. The role of these genetic modifiers in reducing the severity of the disease in tribal groups was first shown by studies done in Odisha
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. Subsequently, studies have shown that tribal groups in Gujarat and Maharashtra have a milder presentation than non-tribal populations with the rates of painful crises, infections, acute chest syndrome and hospitalizations being fewer in them. This has partly been attributed to the very high prevalence of α-thalassaemia (90 to 97 %) in some tribes and/ or much higher foetal haemoglobin (HbF) levels 44, 45 . However, a few sickle cell disease patients among tribal populations have a more severe disease and have benefitted from hydroxyurea therapy
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. The efficacy of hydroxyurea therapy in sickle cell disease patients in different regions in India having the Arab-Indian haplotype have been summarized recently 17 .
Delivering health care to tribal populations is a challange and a village based model has been described in Bardoli in Gujarat where an outreach programme is being undertaken with the help of a mobile clinical unit and a local villager has also been given basic health care training to regularly visit and monitor sickle cell disease patients and send those with significant complications to the hospital coordinating the programme 47 . The possibility of comprehensive integrated care of patients with sickle cell disease has also been demonstrated in a remote tribal population in Gudalur in south India where 71 per cent of the 111 patients had at least one annual comprehensive clinic visit and 0.7 painful episodes per year were reported. This study also reported premature deaths in 19 patients at a median age of 23 yr due to acute chest syndrome, sepsis, severe anaemia, stroke, mesenteric infarction or sudden unexplained death 48 .
There are little data on the maternal and perinatal outcomes of women with sickle cell disease in India. A prospective study from Odisha showed that neonatal outcomes such as low birth weight, perinatal mortality rate, admissions to the neonatal care unit, intrauterine growth retardation and preterm births were significantly higher in sickle cell anemia mothers with successful pregnancies being achieved in 84.44 per cent of cases 49 . Maternal and perinatal outcomes were also evaluated retrospectively from patients' case files in women with sickle cell disease in a tribal population in Madhya Pradesh. There were 25 deliveries to women with sickle cell disease and preeclampsia and disseminated intravascular coagulation were common problems. There was no maternal mortality; however, there were five intrauterine foetal deaths and one early neonatal death 50 .
Prenatal diagnosis
Although there are significant advances in the management of sickle cell disease, yet increased morbidity and early death are not infrequent. Thus, prenatal diagnosis remains an important option for couples at risk of having a child with homozygous sickle cell anaemia, sickle-β-thalassaemia or HbSD disease despite the fact that it is impossible to predict the severity of the disease and many individuals may have a milder clinical presentation. With increasing awareness in the community more couples are opting for prenatal diagnosis 51, 52 . In our experience of around 400 prenatal diagnosis for sickle cell disorders about 20 per cent were tribal couples mainly from South Gujarat, Maharashtra, Madhya Pradesh and Odisha. Chorionic villus sampling at 10 to 12 wk of gestation and DNA analysis by reverse dot blot hybridization or allele specific priming were the methods of choice for prenatal diagnosis. Unlike in the caste populations where a large spectrum of β-thalassaemia mutations are seen, among tribal groups only two β-thalassaemia mutations [(IVS1-5(G>C) and Codon 15(G>A)] are common accounting for around 90 per cent of the β-thalassaemia alleles 53 .This makes prenatal diagnosis simpler and more cost-effective in tribal populations. For couples who came late, cordocentesis and foetal blood analysis by HPLC were done. These technologies have now been established at regional centres.
Integration of medical genetic services in primary health care
Most of the tribal populations where sickle cell disease is common rely on the primary health care facilities in rural and often remote areas. Thus, the goals of medical genetic services should be to help these people with a genetic disadvantage and their families to have access to quality care as well as social and genetic counselling support to make informed choices for reproduction to have healthy children with the availability of prevention programmes when needed. The Indian Council of Medical Research (ICMR) under its Tribal Health Research Forum (THRF) activities as well as other programmes under the National Rural Health Mission (NRHM) in different States have initiated programmes to enable advances in genetics to reach these communities.
